Duke Cancer Institute’s Post

Thank you for the amazing research from Nicole Scheff, PhD and Dan Zandberg, MD. We are incredibly excited to see the publication in the Journal for ImmunoTherapy of Cancer (JITC) showing that opioids are immunosuppressive in head and neck cancer and that axelopran reverses it. With 45% of ICI patients relying on opioids for pain relief, these findings could significantly influence how we approach cancer therapies. At Glycyx, we’re pioneering solutions to address Opioid-Induced Immunotherapy Failure (OIIF), aiming to enhance ICI efficacy and improve outcomes for cancer patients worldwide. Our lead asset, Axelopran, is designed to reverse opioid-induced immunosuppression, increase immune cell infiltration into tumors to maximize the efficacy of ICIs. This breakthrough in collaboration with UPMC reflects Glycyx’ commitment to advancing innovative science for better patient care. Thank you Lorin Johnson and Dave Taggart as you both continue to push scientific breakthroughs for Glycyx. https://lnkd.in/gF-NJ8yk #axelopran #glycyx #CancerResearch #oncology #immunooncology #checkpointinhibitors

It's World Pancreatic Cancer Today, and we can never say it enough: pancreatic cancer is silent but deadly. 💥 🎗 When we think of cancer, lung and breast cancer often come to mind because of their prevalence and the extensive awareness efforts surrounding them. However, pancreatic cancer remains largely unnoticed, despite being a serious challenge with one of the highest mortality rates among all cancers and a rising incidence. Its propensity for late detection makes it far deadlier than many realise. As the number of cases continues to rise, it is crucial to spotlight this relentless disease, explore why it is so difficult to treat, and examine ongoing efforts to change its trajectory. ▶ Read more in this blog written by Michael Maris, PhD, MBA: https://lnkd.in/eH3Pt-zD #anticancerfund #cancerresearch #pancreaticcancer Pancreatic Cancer Europe Pancreatic Cancer Action Network

Early detection is key. Make sure to get screened!

🌟 Thrilled to Announce 🌟 I am incredibly honored to share that our poster, titled "Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+ and HER2-low Breast Cancer: An Updated Systematic Review and Meta-analysis of Clinical Trials," has been accepted at ASCO 2024. This marks not only a significant milestone in our journey to improve breast cancer treatment but also a testament to the hard work and dedication of our incredible team. This research synthesizes the latest clinical trials, offering new insights into the safety profiles and efficacy of trastuzumab deruxtecan in treating both HER2+ and HER2-low metastatic breast cancer. Our findings could pave the way for more personalized and effective treatment strategies, impacting patients worldwide. Join us at ASCO 2024 to dive deeper into our research and explore its potential implications for the future of breast cancer therapy. Your insights, questions, and discussions enrich our collective understanding and drive forward the pursuit of excellence in cancer care. Together, we are moving closer to a future where cancer treatment is more effective, less invasive, and highly personalized. Let’s continue to push the boundaries of what’s possible. #ASCO2024 #BreastCancerResearch #OncologyInnovation #TrastuzumabDeruxtecan #HER2Positive #HER2Low #CancerCare #MedicalResearch #HealthcareInnovation

🎉 Congratulations to Simon Haas and his team! They have been awarded a €150,000 Proof-of-Concept Grant from the European Research Council (ERC). Immunotherapies leverage the body's immune system to fight cancer, and Haas' team is developing methods within the Single Cell focus of Berlin Institute of Health in der Charité, #mdcBerlin, and Charité - Universitätsmedizin Berlin to predict the effectiveness of these therapies. 🛌 Immunotherapies, already successful in treating leukemia, work by enhancing the ability of immune cells to detect and destroy cancer cells. However, this expensive treatment only benefits a fraction of patients, and resistance can develop. Predicting which patients will benefit from immunotherapy has been challenging until now. 🔬 Simon Haas and his team have developed novel methods based on single-cell analysis to precisely analyze interactions between immune and cancer cells. These methods aim to predict which patients will benefit from immunotherapies, helping to tailor treatments more effectively and reduce costs for the healthcare system. 🏥 The ERC grant will support the translation of their research into clinical application, marking a significant step toward market readiness. Congratulations to Simon Haas, his team, and Schayan Yousefian, who is leading the project’s implementation. This recognition by the ERC underscores the importance and potential impact of their work. #ERCGrant

As we recognize Breast Cancer Awareness Month, it’s vital to reflect on both our progress and the challenges we still face. In 2024, an estimated 310,720 new cases of invasive breast cancer will be diagnosed in the U.S. alone, with about 42,250 women expected to die from the disease. While advances in early detection—particularly in hormone receptor-positive breast cancer—have improved survival rates, we must remain focused on the continued rise in diagnoses among younger women, with incidence increasing by 1.4% annually in women under 50. In recent years, breast cancer treatment has shifted toward targeted therapies aimed at improving outcomes while reducing the physical toll on patients. These therapies focus on specific molecular pathways that drive cancer growth, offering more precise treatments with fewer side effects. The ongoing development of these approaches holds promise for not only extending survival but also improving patients’ quality of life, allowing them to navigate treatment with greater resilience and strength. I feel privileged to be part of a community of researchers, clinicians, and advocates all dedicated to improving care for women everywhere. Together, we are moving closer to a future where every woman diagnosed with breast cancer has access to better, more personalized treatments that not only save lives but also support recovery and well-being. #BreastCancerAwareness #BreastCancerResearch #TargetedTherapies #WomensHealth #InnovatingForChange #BreastCancerAwarenessMonth #BreastCancer

🔬 Exciting news! A recent study, which included ICARE participants, suggests the life-saving potential of preventive mastectomy for BRCA1 and BRCA2 carriers. 💪 This procedure significantly reduces the risk of developing breast cancer and may even decrease the risk of breast cancer-related mortality. The study found that after preventive mastectomy, the chance of dying from breast cancer was less than 1%. Follow us for more groundbreaking insights in hereditary cancer research! 🌟 Learn more at: https://lnkd.in/gKbrSGbz Reference: Metcalfe, et al. Br J Cancer. 2024;130(2):269-274. PMID: 38030749. #ICARE #InheritedCancerRegistry #InheritedCancer #HereditaryCancer #Cancer #BreastCancer #BRCA1 #BRCA2 #BRCA #CancerGenetics #GeneticTesting #Genomics #CancerGenomics #CancerRisks #CancerRiskManagement #CancerPrevention #PreventiveMastectomy #BreastCancerSurgery #CancerResearch American Society of Clinical Oncology (ASCO) American Cancer Society National Cancer Institute (NCI) Vanderbilt Health Vanderbilt-Ingram Cancer

CCCZ Strategy Workshop Highlights – 08.07.2024   Our latest CCCZ Strategy Workshop brought forward critical discussions and strategic initiatives aimed at enhancing the CCCZ's role in the Swiss cancer care landscape. Here are the key takeaways:   - Patient Pathways: Launch of a pilot pathway at CCCZ for lung cancer patients with dedicated care coordinators to guide the patient’s journey through the cancer center. - Clinical Trials: The CCCZ is focused on the development of state-of-the-art clinical trials program allowing our patients to benefit from novel diagnostic and therapeutic concepts and the latest research results. - Supportive Services: Enhancing collaboration among >15 supportive care services at the CCCZ to offer cancer patient comprehensive physical, psychosocial and emotional care. - National Cancer Plan Switzerland: The CCCZ aims to support this truly important initiative of a Swiss wide strategy and collaboration in prevention, treatment, and aftercare to beat cancer.   This workshop marks a pivotal step in aligning our strategies and improving our collaborative efforts to enhance cancer medicine and research in Zurich.   #CancerCare #CCCZ #StrategyWorkshop #HealthcareInnovation #Oncology #ClinicalTrials #PatientCare #MedicalResearch #HealthcareStrategy

We are thrilled to unveil the positive results from our Phase 2 CORE-001 trial at #ASCO24, showcasing cretostimogene grenadenorepvec in combination with pembrolizumab as a promising therapy for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-#NMIBC) with Carcinoma in Situ (CIS). Sharing these results on #NationalCancerSurvivorsDay highlights the profound impact of our work, aligning our scientific advancements with a day that honors the resilience and perseverance of #bladdercancer survivors. 👉 Explore our findings at ASCO Poster Board #296 (Abstract #4601) We extend our gratitude to Roger Li, M.D., from Moffitt Cancer Center, for his outstanding presentation (Abstract Number: 4601). Our work cannot be done alone, and thank you to our courageous patients and dedicated collaborators. Your dedication to innovative cancer research provides real-world data, driving our progress in advancing cretostimogene as a potential backbone therapy in bladder cancer. Thank you for inspiring us every step of the way. #CORE001 #UroOncology #CancerResearch #ClinicalResearch #PatientCare #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #CGOncology #cretostimogene

Phase 2 CORE-001 trial at #ASCO24, showcasing cretostimogene grenadenorepvec in combination with pembrolizumab as a promising therapy for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-#NMIBC) with Carcinoma in Situ (CIS). Sharing these results on #NationalCancerSurvivorsDay highlights the profound impact of our work, aligning our scientific advancements with a day that honors the resilience and perseverance of #bladdercancer survivors.